Join our networking event in Boston for a great opportunity to discuss the path to success in entrepreneurship! 

Organized by MECUSA, the gender equity committee within ECUSA.

A 1-hour roundtable with 3 guest speakers involved in entrepreneurship, followed by a networking session with complimentary snacks and drinks. We will talk about transferring innovations from academia to industry, founding your own company and leading biotech companies that develop cutting-edge technologies. 

Do not miss the opportunity to learn from and connect with other entrepreneurs!

Free registration here

Meet our speakers:

Alba Chacon Cabrera is a Senior Manager in the Business Development and Licensing team at the Innovation Office of Mass General Brigham in Boston. Dr. Chacon completed her PhD at the Universitat Pompeu Fabra in Barcelona and trained as a postdoctoral fellow at the Memorial Sloan Kettering Cancer Center in New York. Dr. Chacon has worked in the Innovation Office of Mass General Brigham since 2018, where she helps academic researchers transfer their innovations to industry.

Samantha Johnson is the Founder of Tatum Robotics. She obtained her Bioengineering bachelor’s and master’s at Northeastern University. After completing her master’s thesis creating a fingerspelling robotic arm to aid in communication for the DeafBlind community, she founded Tatum Robotics, where she is now pursuing her passion for accessibility by continuing development on this assistive technology. Tatum Robotics aims to offer people with deafblindness, a historically underserved community, their first independent communication tool. 

Laura Sepp-Lorenzino is the Chief Scientific Officer at Intellia Therapeutics, Inc. Dr. Sepp-Lorenzino obtained a PhD in Biochemistry from the New York University and worked at the Memorial Sloan Kettering Cancer Center before starting her career in industry. Dr. Sepp-Lorenzino counts with extensive experience in several pharmaceutical companies, including Merck, Alnylam Pharmaceuticals and Vertex Pharmaceuticals. She joined Intellia Therapeutics in 2019, and has since then enabled the advancement of gene editing therapies, including the first-in-human trial of liver-directed  in vivo gene editing therapies.  

Free registration here